𝐙𝐨𝐞𝐭𝐢𝐬 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐀𝐧𝐢𝐦𝐚𝐥 𝐖𝐞𝐚𝐤𝐧𝐞𝐬𝐬 𝐃𝐫𝐢𝐯𝐞𝐬 𝐀 𝐒𝐡𝐚𝐫𝐩 𝐅𝐮𝐥𝐥𝐘𝐞𝐚𝐫 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐂𝐮𝐭

$ZTS (+0,52%)

⠀

𝐑𝐞𝐬𝐮𝐥𝐭𝐬

• Adj. EPS: $1.87, +5% YoY

• Revenue: $2.5B, flat YoY

• Adj. Net Income: $781M, -1%

• Organic Operational Revenue: -1%

• Organic Operational Adj. Net Income: -2%

⠀

𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞

• FY26 Revenue: $9.12B–$9.32B

• Organic Operational Revenue Growth: -3% to -1%

• FY26 Adj. Net Income: $2.57B–$2.62B

• Organic Operational Adj. Net Income Growth: -9% to -5%

• FY26 Adj. EPS: $6.15–$6.25

⠀

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬

• U.S. revenue fell 7%, with Companion Animal sales down 11% as softer clinic visits, pet-owner price sensitivity and stronger competition pressured dermatology, Simparica Trio and Librela

• U.S. Livestock sales rose 23%, supported by strength in cattle and poultry

• International revenue grew 8% reported and 6% organically, led by parasiticides, diagnostics and new osteoarthritis pain launches

• Zoetis continues to advance a pipeline containing more than 12 potential blockbuster candidates

• The company completed its acquisition of veterinary teleradiology platform VitalRADS, expanding its diagnostics offering

ShindyDeanMartin@ShindyDeanMartin

2Mês

The guidance is, after all, disastrous

••

Nuno F.@Nunalho

Disastrous for short-term traders, sure. But for long-term dividend growth investors, it’s a temporary bump in a quality moat. Pets aren't going anywhere, International is still growing (+8%), Livestock pulled through (+23%), and the payout ratio (~39%) leaves a massive safety margin for the dividend. Perfect setup for patience.

•

𝐙𝐨𝐞𝐭𝐢𝐬: 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐀𝐧𝐢𝐦𝐚𝐥 𝐖𝐞𝐚𝐤𝐧𝐞𝐬𝐬 𝐃𝐫𝐢𝐯𝐞𝐬 𝐀 𝐒𝐡𝐚𝐫𝐩 𝐅𝐮𝐥𝐥-𝐘𝐞𝐚𝐫 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐂𝐮𝐭